A primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a and its application
By designing the combination of gRNA transcription primer and multiple PCR amplification technology based on CRISPR-Cas14a, the problems of expensive detection equipment and base resolution limitation in the prior art are solved, and the drug resistance to Mycobacterium tuberculosis are achieved quickly and accurately Testing is suitable for use in grassroots hospitals.
Patent Information
- Application Number
- CN202410912380.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-07-09
AI Technical Summary
The existing detection methods for M. tuberculosis resistance require expensive instruments or have base resolution limitations, making it difficult to promote and apply in primary hospitals, and there are limitations in specific identification of SNPs.
A combination of gRNA transcription primers based on CRISPR-Cas14a was designed to detect drug resistance-related sites of Mycobacterium tuberculosis, and target-specific gRNA was obtained through multiplex PCR amplification and in vitro transcription, and the CRISPR-Cas14a detection system was used to achieve rapid development. , accurate drug resistance detection.
It realizes rapid and accurate detection of drug resistance to Mycobacterium tuberculosis, has good specificity, high sensitivity, simple methods, and is suitable for promotion and application in grassroots hospitals, avoiding the dependence of expensive equipment.
Smart Images

Figure CN118460751B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nucleic acid detection and genotyping in biomedicine, and in particular to a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a and an application thereof. Background Art
[0002] At present, the global treatment success rate of drug-resistant tuberculosis (DR-TB) is 60%, which is still low. Among anti-tuberculosis drugs, rifampicin and isoniazid are the two most effective first-line anti-tuberculosis drugs, and resistance to these two drugs is the most worrying. At present, the cure rate of drug-resistant tuberculosis, especially multidrug-resistant pulmonary tuberculosis patients, is low and the mortality rate is high, which has caused serious harm to human health. Therefore, it is crucial to accurately and promptly diagnose tuberculosis and drug resistance in order to initiate appropriate treatment and effectively control the disease while preventing its further spread. At present, the diagnostic techniques for drug-resistant tuberculosis mainly include bacteriological detection methods and molecular biological detection methods. Bacteriological diagnostic methods must first be based on the results of positive tuberculosis culture, and the drug resistance is judged according to the growth and metabolic status of tuberculosis. At present, traditional drug sensitivity tests are still the gold standard for the diagnosis of drug-resistant tuberculosis. However, due to the slow growth rate of tuberculosis, traditional solid drug sensitivity tests usually take 3 months to obtain drug sensitivity results, which can easily delay the treatment of drug-resistant tuberculosis patients.
[0003] In recent years, the rapid development of molecular biological diagnostic technology has provided an important means for the rapid diagnosis of tuberculosis and drug-resistant tuberculosis. The detection method based on molecular biology can save the process of culturing bacteria, which greatly shortens the diagnosis time of tuberculosis and drug-resistant tuberculosis. Currently, the more popular molecular biological detection methods mainly include GeneXpertMTB / RIF, linear probe technology (MTBDR plus), high resolution melting curve technology (High Resolution Melting, HRM), gene chip technology and whole genome sequencing (Whole Genome Sequencing, WGS). GeneXpert MTB / RIF was developed by Cepheid, USA, and is currently the most widely used molecular detection method for rifampicin resistance. The system has a very high degree of automation, simple operation, short time consumption, low cross contamination, and safety to the environment and laboratory personnel. It is the rifampicin resistance detection technology recommended by the World Health Organization, but the detection system can only detect rifampicin resistance, and the technical equipment and related reagents are imported from abroad, which is expensive. Linear probe technology (MTBDR plus) can detect rifampicin, isoniazid and multidrug resistance sites, providing a new means for drug resistance detection, and making up for the defect that GeneXpert MTB / RIF technology can only detect rifampicin resistance. However, this technology requires DNA extraction during operation, and the degree of automation is not as good as GeneXpertMtb / RIF, which is prone to false negatives. High Resolution Melting (HRM) is a method of designing specific primers for genes with high frequency of drug resistance mutations, combining real-time PCR and HRM to quickly detect MDR-TB. This method has intuitive results, is easy to judge, has high sensitivity, and cheap consumables. It takes 2-3 days, but there are certain false positives. Gene chip technology and whole genome sequencing (WGS) can detect gene mutations at multiple drug resistance sites with high accuracy, but the cost is relatively high. They are currently mostly used in scientific research. Although molecular biological detection technology can quickly diagnose the drug resistance of tuberculosis, the current methods require expensive instruments, which is not conducive to the promotion and application of primary hospitals. Moreover, current molecular biological detection methods are mainly based on the principles of nucleic acid or probe hybridization to detect tuberculosis drug resistance. Due to the limitation of resolution, these methods have certain limitations in the specific identification of SNPs.
[0004] CRISPR-Cas12a and CRISPR-Cas13a are widely used in nucleic acid detection, but their application in bacterial resistance detection has rarely been reported in the literature. This is because CRISPR-Cas12a and CRISPR-Cas13a require PAM motifs for substrate recognition, and it is challenging to achieve single-base resolution without introducing additional mutant bases in gRNA. Summary of the invention
[0005] The main purpose of the present invention is to propose a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis and its application, aiming to solve the current methods for detecting drug resistance of Mycobacterium tuberculosis, which either require expensive instruments, which is not conducive to the promotion and application in primary hospitals, or are limited by base resolution and have certain limitations.
[0006] To achieve the above object, the present invention proposes a gRNA transcription primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a, wherein the primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a includes a gRNA transcription primer combination, and the gRNA transcription primer combination includes:
[0007] The wild type rpoB-1349C at the 1349 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1349C is shown in SEQ ID NO.7;
[0008] A mutant rpoB-1349T at position 1349 of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-1349T is shown in SEQ ID NO.8;
[0009] A mutant rpoB-1349G at position 1349 of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-1349G is shown in SEQ ID NO.9;
[0010] The wild type rpoB-1333C at the 1333 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1333C is shown in SEQ ID NO.10;
[0011] A mutant rpoB-1333T at the 1333 site of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-1333T is shown in SEQ ID NO.11;
[0012] A mutant rpoB-1333G at site 1333 of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-1333G is shown in SEQ ID NO.12;
[0013] The wild type rpoB-1334A at the 1334 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1334A is shown in SEQ ID NO.13;
[0014] A mutant rpoB-1334T at site 1334 of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of the rpoB-1334T is shown in SEQ ID NO.14;
[0015] A mutant rpoB-1334G at site 1334 of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-1334G is shown in SEQ ID NO.15;
[0016] Wild-type rpoB-1303-1304-GA at the 1303-1304 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1303-1304-GA is shown in SEQ ID NO.16;
[0017] A mutant rpoB-1303T at the 1303 site of the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of the rpoB-1303T is shown in SEQ ID NO.17;
[0018] The mutant rpoB-1304T at the 1304 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1304TC is shown in SEQ ID NO.18;
[0019] The wild-type inhA-777G at the -777 site of the inhA gene of Mycobacterium tuberculosis, the sequence of which is shown in SEQ ID NO.19;
[0020] A sequence of the mutant inhA-777A at the -777 site of the inhA gene of Mycobacterium tuberculosis, wherein the inhA-777A is shown in SEQ ID NO.20;
[0021] A wild-type katG-944G at the 944 mutation site of the KatG gene of the Mycobacterium tuberculosis, wherein the sequence of the katG-944G is shown in SEQ ID NO.21;
[0022] a mutant katG-944C targeting the KatG gene 944 site of the Mycobacterium tuberculosis, wherein the sequence of the katG-944C is shown in SEQ ID NO.22; and
[0023] The mutant katG-944A targeting the 944 mutation site of the KatG gene of Mycobacterium tuberculosis, the sequence of the katG-944A is shown in and SEQ ID NO.23.
[0024] The multiplex PCR amplification primers include:
[0025] rpoB-F and rpoB-R designed for the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-F is shown in SEQ ID NO.1 and the sequence of rpoB-R is shown in SEQ ID NO.2;
[0026] KatG-F and KatG-R designed for the mutation site of the katG gene of Mycobacterium tuberculosis, wherein the sequence of KatG-F is shown in SEQ ID NO.3 and the sequence of KatG-R is shown in SEQ ID NO.4; and,
[0027] inhA-F and inhA-R are designed for the mutation site of the inhA gene of Mycobacterium tuberculosis, the sequence of inhA-F is shown in SEQ ID NO.5 and the sequence of inhA-R is shown in SEQ ID NO.6.
[0028] The present invention provides a kit for detecting drug resistance-related mutation sites of Mycobacterium tuberculosis, comprising the multiplex PCR amplification primers as described above and the multiplex PCR amplification primers as described above.
[0029] In one embodiment, a method for detecting drug resistance of Mycobacterium tuberculosis comprises the following steps:
[0030] S10, providing the kit as described above;
[0031] S20, respectively mixing the gRNA transcription primers for each target in the gRNA transcription primer combination with T7-R, using the synthesized gRNA backbone DNA as a template, amplifying the DNA template applied to gRNA transcription, using the DNA template as a gRNA transcription template, and synthesizing in vitro transcription to obtain target-specific gRNA;
[0032] S30, amplifying the target gene using multiple PCR amplification primers to obtain PCR products;
[0033] S40, mixing the PCR product with the CRISPR-Cas14a detection system to obtain a fluorescent signal, and determining the type of drug resistance of Mycobacterium tuberculosis according to the strength of the fluorescent signal, wherein the CRISPR-Cas14a detection system includes a target-specific gRNA.
[0034] In one embodiment, the CRISPR-Cas14a detection system further includes: a buffer, Cas14a, an FQ reporter gene and a T7 exonuclease.
[0035] The present invention also provides a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a, which is used in the preparation of a diagnostic reagent, a test strip or a biosensor for detecting drug resistance of Mycobacterium tuberculosis.
[0036] The invention discloses a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a. The primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a includes a gRNA transcription primer combination, and the gRNA transcription primer combination is designed for common mutation sites of rifampicin resistance and isoniazid resistance. The gRNA transcription primer combination can be used to amplify a gRNA transcription DNA template, and target-specific gRNA required for detection is obtained by in vitro transcription. In subsequent applications, the drug resistance-related mutation sites of Mycobacterium tuberculosis can be specifically identified and authenticated, so that the drug resistance of Mycobacterium tuberculosis can be detected quickly and accurately, with good specificity, high sensitivity, simple method, and easy promotion. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.
[0038] Figure 1 Schematic diagram of electrophoresis results of multiplex PCR amplification primers designed for one embodiment of the present invention:
[0039] Figure 2 Schematic diagram of the effectiveness test results of the gRNA combination designed for one embodiment of the present invention.
[0040] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION
[0041] To make the purpose, technical scheme and advantages of the embodiment of the present invention clearer, the technical scheme in the embodiment of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiment, it is carried out according to the normal conditions or the conditions recommended by the manufacturer. If the reagents or instruments used do not specify the manufacturer, they are all conventional products that can be purchased commercially. In addition, the meaning of "and / or" appearing in the full text includes three parallel schemes, taking "A and / or B" as an example, including scheme A, or scheme B, or schemes that A and B meet at the same time. In addition, the technical schemes between the various embodiments can be combined with each other, but must be based on the ability of ordinary technicians in the field to achieve. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that the combination of such technical solutions does not exist, and is not within the scope of protection required by the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work belong to the scope of protection of the present invention.
[0042] At present, linear probe technology can detect rifampicin, isoniazid and multidrug resistance sites, providing a new means for drug resistance detection, and making up for the defect that GeneXpert MTB / RIF technology can only detect rifampicin resistance. However, this technology requires DNA extraction during operation, and the degree of automation is not as good as GeneXpert Mtb / RIF, which is prone to false negatives. High Resolution Melting (HRM) is a method of designing specific primers for genes with high frequency of drug resistance mutations, combining real-time PCR and HRM to quickly detect MDR-TB. This method has intuitive results, is easy to judge, has high sensitivity, and cheap consumables. It takes 2-3 days, but there are certain false positives. Gene chip technology and whole genome sequencing (WGS) can detect gene mutations at multiple drug resistance sites with high accuracy, but the cost is relatively high. They are currently mostly used in scientific research. Although molecular biological detection technology can quickly diagnose the drug resistance of tuberculosis, the current methods require expensive instruments, which is not conducive to the promotion and application of primary hospitals. Moreover, current molecular biological detection methods are mainly based on the principles of nucleic acid or probe hybridization to detect tuberculosis drug resistance. Due to the limitation of resolution, these methods have certain limitations in the specific identification of SNPs.
[0043] In view of this, the present invention proposes a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a, wherein the primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a includes a gRNA transcription primer combination, and the gRNA transcription primer combination includes:
[0044] For the wild type rpoB-1349C at the 1349 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1349C is shown in SEQ ID NO.7, and the sequence of the rpoB-1349C is specifically:
[0045] CGCCGACTGTCGGCGCTGGGGTTGCATTCCTTCATTCTTTC;
[0046] For the mutant rpoB-1349T at the 1349 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1349T is shown in SEQ ID NO.8, and the sequence of the rpoB-1349T is specifically:
[0047] CGCCGACTGTTGGCGCTGGGGTTGCATTCCTTCATTCTTTC;
[0048] For the mutant rpoB-1349G at the 1349 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1349G is shown in SEQ ID NO.9, and the sequence of the rpoB-1349G is specifically:
[0049] CGCCGACTGTGGGCCGCTGGGGTTGCATTCCTTCATTCTTTC;
[0050] For the wild-type rpoB-1333C at the 1333 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of rpoB-1333C is shown in SEQ ID NO.10, and the sequence of rpoB-1333C is specifically:
[0051] GGGGTTGACCTACAAGCGCCGTTGCATTCCTTCATTCTTTC;
[0052] For the mutant rpoB-1333T at the 1333 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1333T is shown in SEQ ID NO.11, and the sequence of the rpoB-1333T is specifically:
[0053] GGGGTTGACCGACAAGCGCCGTTGCATTCCTTCATTCTTTC;
[0054] For the mutant rpoB-1333G at the 1333 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1333G is shown in SEQ ID NO.12, and the sequence of the rpoB-1333G is specifically:
[0055] GGGGTTGACCAACAAGCGCCGTTGCATTCCTTCATTCTTTC;
[0056] For the wild-type rpoB-1334A at the 1334 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1334A is shown in SEQ ID NO.13, and the sequence of the rpoB-1334A is specifically:
[0057] GGGGTTGACCCACAAGCGCCGTTGCATTCCTTCATTCTTTC;
[0058] For the mutant rpoB-1334T at the 1334 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1334T is shown in SEQ ID NO.14, and the sequence of the rpoB-1334T is specifically:
[0059] GGGGTTGACCCTCAAGCGCCGTTGCATTCCTTCATTCTTTC;
[0060] For the mutant rpoB-1334G at the 1334 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1334G is shown in SEQ ID NO.15, and the sequence of the rpoB-1334G is specifically:
[0061] GGGTTGACCCGCAAGCGCCGGTTGCATTCCTTCATTCTTTC;
[0062] The wild-type rpoB-1303-1304-GA at the 1303-1304 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1303-1304-GA is shown in SEQ ID NO.16, and the sequence of the rpoB-1303-1304-GA is specifically:
[0063] CCAATTCATGGACCAGAACAGTTGCATTCCTTCATTCTTTC;
[0064] For the mutant rpoB-1303T at the 1303 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1303T is shown in SEQ ID NO.17, and the sequence of the rpoB-1303T is specifically:
[0065] CCAATTCATGTACCAGAACAGTTGCATTCCTTCATTCTTTC;
[0066] For the mutant rpoB-1304T at the 1304 site of the rpoB gene of Mycobacterium tuberculosis, the sequence of the rpoB-1304TC is shown in SEQ ID NO.18, and the sequence of the rpoB-1304TC is specifically:
[0067] CAATTCATGGTCCAGAACAAGTTGCATTCCTTCATTCTTTC;
[0068] For the wild-type inhA-777G at the -777 site of the inhA gene of Mycobacterium tuberculosis, the sequence of inhA-777G is shown in SEQ ID NO.19, and the sequence of inhA-777G is specifically:
[0069] CGCGGCGAGACGATAGGTTGGTTGCATTCCTTCATTCTTTC;
[0070] The sequence of the mutant inhA-777A at the -777 site of the inhA gene of Mycobacterium tuberculosis, wherein the inhA-777A is as shown in SEQ ID NO.20, and the inhA-777A sequence is specifically:
[0071] CGCGGCGAGATGATAGGTTGGTTGCATTCCTTCATTCTTTC;
[0072] The wild-type katG-944G at the 944 mutation site of the KatG gene of Mycobacterium tuberculosis, the sequence of the katG-944G is shown in SEQ ID NO.21, and the specific sequence of the katG-944G is:
[0073] GCGATCACCAGCGGCATCGAGTTGCATTCCTTCATTCTTTC;
[0074] For the mutant katG-944C at the 944 site of the KatG gene of Mycobacterium tuberculosis, the sequence of the katG-944C is shown in SEQ ID NO.22, and the specific sequence of the katG-944C is:
[0075] GCGATCACCAACGGCATCGAGTTGCATTCCTTCATTCTTTC; and,
[0076] For the mutant katG-944A at the 944 mutation site of the KatG gene of Mycobacterium tuberculosis, the sequence of the katG-944A is shown in and SEQ ID NO.23, and the specific sequence of the katG-944A is:
[0077] GCGATCACCACCGGCATCGAGTTGCATTCCTTCATTCTTTC.
[0078] The primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a includes a gRNA transcription primer combination, the gRNA transcription primer combination is designed for common mutation sites of rifampicin resistance and isoniazid resistance, the gRNA transcription primer combination is used to amplify the gRNA transcription DNA template, and obtain the target-specific gRNA required for detection through in vitro transcription, so that the drug resistance of Mycobacterium tuberculosis can be detected quickly and accurately, with good specificity, high sensitivity, simple method and easy promotion.
[0079] It should be noted that gRNA is a small RNA molecule used in CRISPR gene editing technology. The full name of gRNA is "guide RNA". Its function is to guide the Cas protein to target a specific gene sequence. gRNA usually consists of two parts: 1. The guide sequence, which is complementary to the specific sequence of the target gene, so that the Cas protein binds to the target gene; 2. The functional element, usually the RNA element used in the CRISPR system, is used to stabilize the binding of gRNA and Cas protein and ensure that the CRISPR / Cas system can accurately identify and cut the target gene. Usually, short gRNA can be commercially synthesized by the company (mature technology, low synthesis cost), and long gRNA can only be obtained by T7 polymerase in vitro transcription. Since the gRNA base number in this application exceeds 100nt, it can only be obtained by T7 polymerase in vitro transcription.
[0080] By designing appropriate gRNA primers, researchers can achieve editing of specific genes in the genome, such as targeted gene mutation, gene knockout, or insertion of new DNA sequences, making CRISPR technology a powerful tool for studying gene function, treating genetic diseases, and improving crops.
[0081] In one embodiment, the present invention further includes a method for designing and preparing a gRNA primer sequence, comprising the following steps:
[0082] To summarize the mutation sites associated with drug resistance in Mycobacterium nucleatum;
[0083] Select high-frequency sites based on the proportion of mutation sites;
[0084] Design the gRNA transcription primer sequence to match the mutant base to be detected.
[0085] Specifically, by summarizing the common mutation sites of rifampicin resistance and isoniazid resistance in the guidelines and counting the proportion of each resistance mutation site to the total resistance mutation, we selected the highest proportion of RpoB resistance mutation-related sites 1349, 1334, 1333, 1304 and 1303, kat resistance mutation-related site 944, and inhA resistance mutation-related site -777. Multiple gRNA transcription primers were designed for each site, and target-specific gRNA transcription primer combinations were screened through experiments.
[0086] In one embodiment, the primer combination further comprises multiplex PCR amplification primers, wherein the multiplex PCR amplification primers comprise:
[0087] rpoB-F and rpoB-R designed for the rpoB gene of Mycobacterium tuberculosis, wherein the sequence of rpoB-F is shown in SEQ ID NO.1 and the sequence of rpoB-R is shown in SEQ ID NO.2;
[0088] KatG-F and KatG-R designed for the mutation site of the katG gene of Mycobacterium tuberculosis, wherein the sequence of KatG-F is shown in SEQ ID NO.3 and the sequence of KatG-R is shown in SEQ ID NO.4; and,
[0089] inhA-F and inhA-R are designed for the mutation site of the inhA gene of Mycobacterium tuberculosis, the sequence of inhA-F is shown in SEQ ID NO.5 and the sequence of inhA-R is shown in SEQ ID NO.6.
[0090] Specifically, the design is aimed at the mutation site of the rpoB gene, that is, the rifampicin resistance determining region of the rpoB gene, including rpoB-F and rpoB-R, wherein the sequence of rpoB-F is shown in SEQ ID NO.1, specifically: C*A*G*A*TCCGGGTCGGCATGTC; the sequence of rpoB-R is shown in SEQ ID NO.2, specifically: AGACCGATGTTGGGCCCCTC;
[0091] KatG-F and KatG-R designed for the katG gene mutation site of Mycobacterium tuberculosis, wherein the sequence of KatG-F is shown in SEQ ID NO.3, specifically:
[0092] C*T*C*C*GCTGGAGCAGATGGGCTT;
[0093] The sequence of KatG-R is shown in SEQ ID NO.4, specifically:
[0094] TCCCACTCGTAGCCGTACAGGA;
[0095] inhA-F and inhA-R designed for the inhA gene mutation site of Mycobacterium tuberculosis, wherein the sequence of inhA-F is shown in SEQ ID NO.5, specifically:
[0096] G*T*A*A*CCCCAGTGCGAAAGTTCC;
[0097] The sequence of inhA-R is shown in SEQ ID NO.6, specifically:
[0098] AAACAGCCCCTTTGGCGCTC.
[0099] Furthermore, the first five bases in each upstream primer F are thiolated (indicated by *), and only thiolated single-stranded DNA remains after subsequent digestion with T7 enzyme.
[0100] In the present invention, a multiplex PCR amplification primer combination is designed to simultaneously amplify the rifampicin and isoniazid resistance-related genes rpoB, katG and inhA of Mycobacterium tuberculosis, thereby reducing PCR steps and improving detection efficiency.
[0101] The present invention provides a kit for detecting drug resistance-related sites of Mycobacterium tuberculosis, comprising the multiple PCR amplification primers as described above and the gRNA transcription primers as described above. The method does not require expensive detection equipment, has a high speed, and is very suitable for large-scale promotion and application, and will provide a reliable tool for the rapid diagnosis of drug-resistant tuberculosis.
[0102] In one embodiment, a method for detecting drug resistance of Mycobacterium tuberculosis comprises the following steps:
[0103] S10, providing the multiplex PCR amplification primers as described above and the gRNA transcription primer combination as described above;
[0104] S20, respectively mixing the gRNA transcription primers for each target in the gRNA transcription primer combination with T7-R, using the synthesized gRNA backbone DNA as a template, amplifying the DNA template applied to gRNA transcription, using the DNA template as a gRNA transcription template, and synthesizing in vitro transcription to obtain target-specific gRNA;
[0105] S30, amplifying the target gene using multiple PCR amplification primers to obtain PCR products;
[0106] S40, mixing the PCR product with the CRISPR-Cas14a detection system to obtain a fluorescent signal, and determining the type of drug resistance of Mycobacterium tuberculosis according to the strength of the fluorescent signal, wherein the CRISPR-Cas14a detection system includes a target-specific gRNA obtained by in vitro transcription.
[0107] This detection method establishes a CRISPR-Cas14a MTB RIF / INH technology platform. By combining gRNA transcription primers for in vitro transcription to obtain the target-specific gRNA required for detection, the Cas14a nuclease can be guided to recognize the target site complementary to the gRNA, thereby activating the non-specific nucleic acid cleavage function of Cas14a, thereby cleaving the fluorescent reporter probe and generating a fluorescent signal, while the non-target site cannot be recognized, so the non-specific nucleic acid cleavage function of Cas14a cannot be activated, thereby not cleaving or weakly cleaving the fluorescent reporter probe and only generating a weak fluorescent signal. The strength of the fluorescent signal can be used to specifically identify and identify the drug resistance-related mutation sites of Mycobacterium tuberculosis, thereby enabling rapid and accurate detection of Mycobacterium tuberculosis drug resistance, with good specificity, high sensitivity, simple method and easy promotion.
[0108] This realizes a dual detection system for rifampicin-resistant tuberculosis and isoniazid-resistant tuberculosis, and the detection steps are simple, fast and easy to promote.
[0109] It is necessary to explain that the gRNA transcription primer combination is designed for the common mutation sites of rifampicin resistance and isoniazid resistance, and the gRNA transcription primer is used to amplify the gRNA transcription DNA template, and obtain the target-specific gRNA required for detection by in vitro transcription. In the subsequent application process, the Cas14a nuclease in the CRISPR-Cas14a detection system can be guided to recognize the target site complementary to the gRNA, thereby activating the non-specific nucleic acid cleavage function of Cas14a, thereby cutting the fluorescent reporter probe and generating a fluorescent signal, while the non-target site cannot be recognized, so the non-specific nucleic acid cleavage function of Cas14a cannot be activated, so the fluorescent reporter probe is not cut or is weakly cut, and only a weak fluorescent signal can be generated. The strength of the fluorescent signal can be specifically identified and identified. Mutation sites related to drug resistance of Mycobacterium tuberculosis, so that the detection of drug resistance of Mycobacterium tuberculosis can be achieved quickly and accurately.
[0110] It should be noted that in step S40, the step of determining the type of drug resistance of Mycobacterium tuberculosis according to multiple fluorescent signals includes: 1) when the CRISPR reaction chamber targeting the wild type generates a fluorescent signal, and the corresponding CRISPR reaction chamber targeting the mutant type has no fluorescent signal, it indicates that the site has not mutated; 2) when the CRISPR reaction chamber targeting the wild type generates a fluorescent signal, and the corresponding CRISPR reaction chamber targeting the mutant type also generates a fluorescent signal, it indicates that the detected substrate contains both wild-type and mutant genotypes; 3) when no fluorescent signal is generated in the CRISPR reaction chamber targeting the wild type, and a fluorescent signal is generated in the corresponding CRISPR reaction chamber targeting the mutant type, it indicates that a mutation has occurred at the site; 4) when no fluorescent signal is generated in the CRISPR reaction chamber targeting the wild type, and no fluorescent signal is generated in the corresponding CRISPR reaction chamber targeting the mutant type, it indicates that a mutation has occurred at a non-resistance-related site.
[0111] In one embodiment, the CRISPR-Cas14a detection system includes: a buffer, gRNA, Cas14a, an FQ reporter gene and a T7 exonuclease.
[0112] It should be noted that Cas14a, a member of the CRISPR family, does not rely on the PAM motif for substrate recognition and can achieve true single-base recognition. Therefore, it is very suitable for detecting drug resistance caused by single-base mutations. The present invention establishes a CRISPR-Cas14a MTB RIF / INH technical platform to realize a dual detection system for rifampicin-resistant tuberculosis and isoniazid-resistant tuberculosis, thereby realizing that CRISPR-Cas14a MTB RIF / INH technology can accurately detect gene mutations related to rifampicin resistance and isoniazid resistance. At the same time, CRISPR-Cas14a MTB RIF / INH technology does not need to rely on expensive detection equipment to realize rifampicin-resistant and isoniazid tuberculosis detection, has low cost and high speed, is very suitable for large-scale promotion and application, and will provide a reliable tool for the rapid diagnosis of drug-resistant tuberculosis.
[0113] The present invention also provides a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a, which is used in the preparation of diagnostic reagents, test strips or biosensors for detecting drug resistance of Mycobacterium tuberculosis. The primer combination can be used to prepare various reagents or reagent strips for detecting drug resistance of Mycobacterium tuberculosis.
[0114] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.
[0115] Example 1: Design and screening of multiplex PCR amplification primers
[0116] In the present invention, for the genes rpoB, katG, and inhA promoter related to rifampicin resistance and isoniazid resistance, multiple PCR amplification primers were designed using Primer Premier V5.0 software to simultaneously amplify rpoB, katG, and inhA promoter (as shown in Table 1), as shown in Table 1. Figure 1 As shown in the figure: In the agarose gel electrophoresis detection of multiple PCR amplification effect, 1 to 9 are tuberculosis strains isolated from nine pulmonary tuberculosis patients respectively, 10 is the negative control, and the designed multiple PCR amplification primers, RpoB, katG and inhA three bands were clearly amplified, and there were no mixed bands, indicating that the designed multiple PCR amplification primers are very successful and can be used in subsequent experiments.
[0117] Table 1 Multiplex PCR amplification primers
[0118]
[0119] Example 2: gRNA primer sequence design, preparation and effectiveness testing
[0120] (1) gRNA primer sequence design
[0121] In the present invention, by summarizing the common mutation sites of rifampicin resistance and isoniazid resistance in patents and guidelines, and statistically analyzing the proportion of each resistance mutation site in the total resistance mutation, KatG-R50L, KatG-R50W, H445Y, H445D, H445L, H445R, D435Y, D435V, KatG-F15T, and inhA_C-15T with the highest proportion were selected for design of gRNA primers.
[0122] gRNA primer sequence design principle: The sequence length of the gRNA primer matching the target is 20bp, and the mutant base to be detected matches the 9th-10th base of the gRNA primer. The primer sequence of gRNA is shown in Table 2 below: (The underlined sequence is the sequence that matches the detection target).
[0123] Table 2 Sequences of gRNA primers in gRNA transcription primer combination
[0124]
[0125] (2) Preparation of gRNA
[0126] The gRNA transcription primers (SEQ ID NO.7~23) for each drug resistance detection site and T7-R (SEQ ID NO.25) were used to amplify the gRNA DNA transcription template from the PUC19 vector containing the T7 promoter gRNA backbone sequence (SEQ ID NO.24) by PCR. The amplified PCR product was used as a DNA template, and the target-specific gRNA was obtained by in vitro transcription at 37°C using the T7 rapid high-yield RNA synthesis kit, and then purified using an RNA purification kit (NEB) to obtain purified gRNA, which was stored at -70°C for future use. The gRNA backbone sequence is as shown in SEQ ID NO.24, and the specific sequence is:
[0127] GTTGCATTCCTTCATTCTTTCAAATGAATTTGTTTCGAGGGTTACTTTCCGAAGAAAGCACTTCTCGACATTAGGCTGATGCAAGCAGCCCACCTTCACTCAAGTTCTAATCCCTAAGGGACAGCTTTTGGTGAAGCGGTTCTCCACTTTATCAGTGAAccctatagtgagtcgtattagaattc;
[0128] The sequence of T7-R is shown in SEQ ID NO.25, and the specific sequence is:
[0129] GAATTCTAATACGACTCACTATAGGGTTCACTGATAAAGTGG.
[0130] (3) Testing of gRNA effectiveness
[0131] The CRISPR-Cas14a detection system includes: 100nM Cas14a, 100nM target-specific gRNA, 100nM FQ reporter gene, 100nM substrate DNA, nuclease detection buffer NEbuffer4.0, and the total reaction volume is 20µl. The reaction is monitored at 37°C for a specified time using a fluorescence plate reader (VarioskanFlash, ThermoFisherScientific, MA, USA). The fluorescence measurement uses an excitation wavelength of 492nm and an emission wavelength of 520nm. The detection results are shown in Figure 2As shown: The ordinate in the figure represents the fluorescence intensity, the abscissa represents the detected wild-type and mutant target ssDNA, and the fluorescence intensity is detected after 1 hour of CRISPR reaction. t-test is used to evaluate significant differences. (n = 3 technical replicates; bars represent mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001), the results show that: in the CRISPR reaction system, when the gRNA detection site is consistent with the site sequence of the substrate ssDNA, the strongest fluorescence signal can be stimulated. If the detection site of the gRNA is inconsistent with the site of the substrate ssDNA, the fluorescence signal is weak. Therefore, from the figure we can see that the screened gRNA can specifically recognize its own target site and cause a strong fluorescence signal, indicating that the designed gRNA can specifically recognize and identify the resistance-related mutation sites of Mycobacterium tuberculosis, and can be used for the detection of rifampicin and isoniazid resistance of Mycobacterium tuberculosis.
[0132] Example 3: Clinical samples to evaluate the feasibility of the CRISPR-CarpoB-F4aMTBRIF / INH method
[0133] (1) Extraction of DNA from sputum samples: A total of 55 sputum samples were collected, and the smear analysis results were positive. RIF and INH drug sensitivity tests were performed on culture-positive patient samples. Among the 55 samples, 8 were identified as multidrug-resistant, 4 showed RIF single resistance, 3 showed INH single resistance, and 41 were sensitive to both RIF and INH. DNA from each sputum sample was extracted using a commercial DNA extraction kit (not limited to company brands).
[0134] (2) Preparation of target DNA: Amplification was performed using the multiplex PCR primers prepared in Example 1 to enrich the target DNA. The multiplex PCR amplification reaction system was based on the multiplexPCRKit (Novozymes, Nanjing, China): 6 μl of multiplex PCR primer combination (the final concentration of each primer was 0.2 μM) and 100 pg of DNA template, with a final volume of 50 μl. The PCR thermal cycle parameters were set as follows: initial denaturation at 95°C for 3 min, 95°C for 30 s, 60°C for 30 s, and 72°C for 1 min for a total of 35 cycles. The final extension step was performed at 72°C for 10 min. After amplification, the PCR products were analyzed using 1% agarose gel electrophoresis.
[0135] (3) CRISPR detection of rifampicin and isoniazid resistance: The CRISPR-Cas14a detection system is composed of 100nM CarpoB-F4a, 100nM gRNA, 100nM FQ reporter gene, 1U T7 exonuclease (NEB) and 2ul multiplex PCR product in NEbuffer4.0 buffer, with a total volume of 20µl. The fluorescence value is measured after incubation at 37°C for 1-2 hours. The fluorescence measurement uses an excitation wavelength of 492nm and an emission wavelength of 520nm.
[0136] (4) Interpretation of drug resistance results: 1) When the CRISPR reaction chamber targeting the wild type produces a fluorescent signal, and the corresponding CRISPR reaction chamber targeting the mutant type has no fluorescent signal, it indicates that the site has not mutated; 2) When the CRISPR reaction chamber targeting the wild type produces a fluorescent signal, and the corresponding CRISPR reaction chamber targeting the mutant type also produces a fluorescent signal, it indicates that the detected substrate contains both wild-type and mutant genotypes; 3) When the CRISPR reaction chamber targeting the wild type does not produce a fluorescent signal, and the corresponding CRISPR reaction chamber targeting the mutant type produces a fluorescent signal, it indicates that the site has mutated; 4) When the CRISPR reaction chamber targeting the wild type does not produce a fluorescent signal, and the corresponding CRISPR reaction chamber targeting the mutant type does not produce a fluorescent signal, it indicates that a non-drug resistance-related site has mutated. This embodiment involves the use of the CRISPR-Cas14aMTBRIF / INH method to evaluate the drug resistance of clinical sputum samples. The sensitivity and feasibility of this method for detecting rifampicin and isoniazid resistance were demonstrated by DNA extraction, target DNA preparation and CRISPR detection of sputum samples.
[0137] (5) Compared with the results of drug sensitivity test, the drug resistance diagnostic performance was detected. The results of drug resistance and sensitivity are shown in Table 3:
[0138] Table 3 Evaluation of the drug resistance diagnostic performance of the CRISPR-Cas14a RIF / INH method in clinical samples
[0139]
[0140] It can be seen from Table 3 that the table gives the results of the drug resistance test and the sensitivity test, as well as the calculated sensitivity and specificity data, and the sensitivity calculation formula is: Sensitivity = number of true positives / (number of true positives + number of false negatives)*100%, specificity = number of true negatives / (number of true negatives + number of false positives).
[0141] According to the data in the table, the resistance performance of rifampicin is evaluated as follows:
[0142] The number of true positives was 12, the number of false negatives was 0, the number of true negatives was 43, and the number of false positives was 2, so the sensitivity result was 12 / (12+2)≈85.7%, and the 95% confidence interval (CI) was (71.2%-93.9%);
[0143] The specificity of rifampicin is 43 / (43+0)=100%, and the 95% confidence interval is (98%, 99.8%).
[0144] According to the data in the table, for the evaluation of isoniazid resistance: the number of true positives is 11, the number of false negatives is 0, the number of true negatives is 44, the number of false positives is 0, the sensitivity of isoniazid is 11 / (11+0)=100%, and the 95% confidence interval (CI) is (90.8%, 99.8%). The specificity of isoniazid is 44 / (44+0)=1=100%, and the 95% confidence interval (CI) is (97.9%-99.7%).
[0145] Based on the above results, it can be concluded that the CRISPR-Cas14aRIF / INH method performed well in the detection of rifampicin resistance and isoniazid drug sensitivity, with high sensitivity and specificity.
[0146] The above are only preferred embodiments of the present invention, and do not limit the patent scope of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the patent protection scope of the present invention.
Claims
1. A primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a, the primer combination comprising a gRNA transcription primer combination, characterized in that: The gRNA transcription primer combination includes: The sequence of the gRNA transcription primer for wild-type rpoB-1349C at site 1349 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.7; The sequence of the gRNA transcription primer for the mutant rpoB-1349T at site 1349 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.8; The sequence of the gRNA transcription primer for the mutant rpoB-1349G at site 1349 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.9; The sequence of the gRNA transcription primer for wild-type rpoB-1333C at site 1333 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.10; The sequence of the gRNA transcription primer for the mutant rpoB-1333T at site 1333 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.11; The sequence of the gRNA transcription primer for the mutant rpoB-1333G at site 1333 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.12; The sequence of the gRNA transcription primer for wild-type rpoB-1334A at site 1334 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.13; The sequence of the gRNA transcription primer for the mutant rpoB-1334T at site 1334 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.14; The sequence of the gRNA transcription primer for the mutant rpoB-1334G at site 1334 of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.15; The sequence of the gRNA transcription primer for the wild-type rpoB-1303-1304-GA at the 1303-1304 site of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.16; The sequence of the gRNA transcription primer for the mutant rpoB-1303T at the 1303 site of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.17; The sequence of the gRNA transcription primer for the mutant rpoB-1304T at the 1304 site of the rpoB gene of Mycobacterium tuberculosis is shown in SEQ ID NO.18; The sequence of the gRNA transcription primer for the wild-type inhA-777G at the -777 site of the inhA gene of Mycobacterium tuberculosis is shown in SEQ ID NO.19; The sequence of the gRNA transcription primer for the mutant inhA-777A at the -777 site of the inhA gene of Mycobacterium tuberculosis is shown in SEQ ID NO.20; The sequence of the gRNA transcription primer for the wild-type katG-944G at the 944 site of the KatG gene of Mycobacterium tuberculosis is shown in SEQ ID NO.21; The sequence of the gRNA transcription primer for the mutant katG-944C at the 944 site of the KatG gene of Mycobacterium tuberculosis is shown in SEQ ID NO.22; and, The sequence of the gRNA transcription primer for the mutant katG-944A targeting the 944 mutation site of the KatG gene of Mycobacterium tuberculosis is shown in SEQ ID NO.23; The primer combination also includes multiple PCR amplification primers, and the multiple PCR amplification primers include: rpoB-F and rpoB-R designed for the rpoB gene of Mycobacterium tuberculosis, wherein the sequences of rpoB-F and rpoB-R are shown in SEQ ID NO.1 and SEQ ID NO.2 respectively; KatG-F and KatG-R designed for the mutation site of the katG gene of Mycobacterium tuberculosis, wherein the sequences of KatG-F and KatG-R are shown in SEQ ID NO.3 and SEQ ID NO.4 respectively; and, inhA-F and inhA-R are designed for the mutation site of the inhA gene of Mycobacterium tuberculosis, and the sequences of inhA-F and inhA-R are shown in SEQ ID NO.5 and SEQ ID NO.6 respectively.
2. A kit for detecting drug resistance-related mutation sites in Mycobacterium tuberculosis, characterized in that: Comprising the gRNA transcription primer combination as described in claim 1.
3. Use of a primer combination for detecting drug resistance-related sites of Mycobacterium tuberculosis based on CRISPR-Cas14a as claimed in claim 1 in the preparation of a reagent for detecting drug resistance of Mycobacterium tuberculosis.
Citation Information
Patent Citations
CrRNA for detecting rifampicin drug resistance point mutation of mycobacterium tuberculosis based on CRISPR-Cas technology
CN114107300A
